(LJPC)

All Comments on LJPC

  • commenter
    User 255438
    Sep 04 12:58 AM
    General Discussion on LJPC
    Take a look at the interview with Dr. Deirdre Gillespie, President and CEO of nearby La Jolla Pharmaceutical. La Jolla is currently in the latter stage of Phase III testing with their unique product, Riquent, which is designed to treat patients with lupus. Riquent employs novel technology, created by La Jolla, in that it is comprised mostly of DNA and sweeps the antibodies that are attacking patients’ DNA out of their bloodstream. Since the commonest causes of ill health among lupus sufferers is caused by the treatments for it—often high dosages of steroids to fight flares—Riquent is used to prevent exacerbations and is therefore, much safer. Dr. Gillespie reveals how the company had to rebound after failing with Riquent in Phase III clinical trials a few years back when it was discovered the dosages were too low. Since then, they have secured another round of funding and have increased the dosage by several factors in the current stage of testing. Dr.Gillespie anticipates they will be able to launch Riquent at some point between now and the end of 2009, depending on the results of ongoing studies

    www.pharmatelevision.c...     Reply
  • commenter
    Frankie62
    May 08 01:23 PM
    Biotech Stocks' Various Lupus Therapies: Opportunity or Lost Cause? [view article]
    It is so sad that there are so few drugs to treat Lupus, and there is no cure. My daughter-in-law has Lupus and would absolutely love to have a baby, but without treatment her Lupus acts up. She was diagnosed in college when she had a major "flare", and even though she is a healthcare professional, she cannot find an adequate treatment. Reply
  • commenter
    SeekingAlpha
    Editors
    Apr 06 05:21 AM
    My Website
    General Discussion on LJPC
    Is this a buy or a sell? Reply
Loading...
Symbols:
Authors:
Quick Links: